A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 18 Sep 2017 NCT reports trial status as active, no longer recruiting and as per MR it is discontinued. kept info as per compnay sponsored MR.
    • 10 Jun 2017 Biomarkers information updated
    • 17 May 2016 Planned End Date changed from 1 Sep 2018 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top